Shield Therapeutics Announces Successful Placing to Raise £32.5 Million and Proposed Admission to AIM

12 Feb 2016

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

London, UK, 12 February 2016. Shield Therapeutics plc (“Shield” or the “Company), a specialty pharmaceutical company focused on the development and commercialisation of secondary care-focused pharmaceuticals, is pleased to announce that it has raised gross proceeds of £32.5 million by way of a placing and subscription of ordinary shares in the capital of the Company (“Ordinary Shares”) and the issue of warrants to subscribe for Ordinary Shares (“Warrants”) to a high quality group of institutional, existing and other investors (the “Placing”) in connection with the admission of its Ordinary Shares and Warrants to trading on the AIM Market of the London Stock Exchange.

The Ordinary Shares and Warrants in Shield are expected to commence trading on AIM by no later than 8:00am GMT on 26 February 2016, under the symbol “STX

Back to news

London, UK

One Euston Square
40 Melton Street
London, NW1 2FD

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

München 5 Höfe
Theatinerstrasse 11
DE- 80333 München

t+49 (0) 89 710 42 2246

einfo.de@shieldtx.com